Ticker

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in…

The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the…

Silence Therapeutics (NASDAQ: SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company's plan to advance a quarterly dosing regimen into Phase III. PV is a rare myeloproliferative neoplasm in which elevated hematocrit levels can

Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company's plan to advance a quarterly dosing regimen into Phase III.